| Literature DB >> 30918037 |
Saurab Sharma1,2, Mark P Jensen3, G Lorimer Moseley4, J Haxby Abbott2.
Abstract
OBJECTIVES: The aims of this study were to: (1) develop pain education materials in Nepali and (2) determine the feasibility of conducting a randomised clinical trial (RCT) of a pain education intervention using these materials in Nepal.Entities:
Keywords: culture; low back pain; low-income country; musculoskeletal pain; pain management; patient education
Year: 2019 PMID: 30918037 PMCID: PMC6475174 DOI: 10.1136/bmjopen-2018-026874
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Steps in the development of pain education handbook. LBP, low back pain.
Baseline characteristics of the two study groups
| Variable | PEG | CG |
| (n=20) | (n=20) | |
| N (%) or mean (SD) | N (%) or mean (SD) | |
| Recruitment, N (%) | ||
| Advertisement | 6 (30) | 6 (30) |
| Hospital | 14 (70) | 14 (70) |
| Sex, N (%) | ||
| Men | 15 (75) | 13 (65) |
| Women | 5 (25) | 7 (35) |
| Marital status | ||
| Married | 16 (80) | 15 (75) |
| Single | 4 (20) | 3 (15) |
| Separated or widowed | 0 (0) | 2 (10) |
| Religion, N (%) | ||
| Hindu | 19 (95) | 16 (80) |
| Buddhist | 1 (5) | 3 (15) |
| Others | 0 (0) | 1 (5) |
| Race/ethnicity, N (%) | ||
| Chettri | 6 (30) | 5 (25) |
| Brahmin | 4 (20) | 9 (45) |
| Newar | 4 (20) | 2 (10) |
| Others | 6 (30) | 4 (20) |
| Education, N (%) | ||
| No school | 3 (15) | 2 (10) |
| Primary school (<5 years) | 3 (15) | 1 (5) |
| Upto high school (6–12 years) | 5 (25) | 8 (40) |
| Bachelor degree and over | 9 (45) | 9 (45) |
| Primary occupation, N (%) | ||
| Business or office work | 13 (65) | 7 (35) |
| Unemployed | 0 (0) | 5 (25) |
| Homemaker | 2 (10) | 3 (15) |
| Currently sick leave for LBP | 1 (5) | 1 (5) |
| Other | 4 (20) | 2 (10) |
| Smoking history, N (%) | ||
| Never smoked | 10 (50) | 12 (60) |
| Currently smoker | 8 (40) | 5 (25) |
| Have quit smoking | 2 (10) | 3 (15) |
| Have left work for more than 1 month due to LBP, N (%) | ||
| Yes | 4 (20) | 4 (20) |
| No | 16 (80) | 16 (80) |
| Medications used for LBP, N (%) | ||
| NSAIDs | 3 (15) | 6 (30) |
| Pregabalin | 2 (10) | 3 (15) |
| Vitamin B12 | 3 (15) | 1 (5) |
| Gabapentin | 1 (5) | 0 (0) |
| Opioids | 1 (5) | 0 (0) |
| Antidepressant | 1 (5) | 0 (0) |
| Secondary outcomes | ||
| Pain intensity* | 54.38 (3.48) | 52.72 (2.45) |
| Pain interference* | 62.28 (6.62) | 58.92 (7.69) |
| Sleep disturbance* | 51.84 (7.68) | 45.63 (8.71) |
| Depression* | 56.99 (8.08) | 53.60 (11.25) |
| Quality of life | 5.70 (1.22) | 6.10 (1.21) |
| Pain catastrophising | 22.70 (10.99) | 20.50 (12.56) |
| Resilience | 26.95 (9.14) | 28.60 (8.08) |
*T scores.
CG, control group; LBP, low back pain; NSAIDs, non-steroidal anti-inflammatory drugs; PEG, pain education group.
Feasibility results for the two study groups
| Feasibility outcomes | PEG | CG | Mean difference (95% CI) or p values | Summary |
| Attrition rate | 1 (5%) | 1 (5%) | 1.000 | No difference in attrition rates between groups. |
| Assessor’s correct guess for group allocation | 12 (60%) | 11 (55%) | 0.756 | Assessor correctly guessed the group allocation slightly more often for the PEG than the CG. |
| Understanding possible contamination between groups (n=19) | No contamination between groups. | |||
| 1. Have you talked to other participants about the intervention? | 0 (0%) | 0 (0%) | – | |
| 2. If yes, was your attitude/intervention changed? | 0 (0%) | 0 (0%) | – | |
| 3. Are you aware of the intervention that participants in the other group are receiving? | 0 (0%) | 0 (0%) | – | |
| 4. Are participants in the other group aware of the type of intervention you are receiving? | 0 (0%) | 0 (0%) | – | |
| 5. For the control group: did you read the pain education booklet provided to the experimental group? | – | 0 (%) | – | |
| Credibility and acceptability of interventions (scale 0–20) | Similar credibility scores between groups. | |||
| Baseline assessment (n=20) | 12.55 (2.89) | 12.95 (3.80) | 0.40 (−2.56 to 1.76) | |
| Final assessment (n=19) | 12.37 (2.63) | 12.26 (4.17) | 0.11 (−2.19 to 2.40) | |
| Adherence to treatment | Participants were adherent to the treatment in both groups, with significantly more adherence reported by the CG participants. | |||
| Followed advice (n=19) | 17 (89%) | 18 (95%) | 0.501 | |
| Performed home exercises (mean days [SD]) | 3.84 (2.43) | 5.53 (1.58) | −1.68 (−3.03 to –0.33) | |
| Number of patients who received other treatments (total) | 5 (26%) | 7 (37%) | 0.471 | Slightly more CG participants received regular physiotherapy at the centre, massage or acupuncture, and NSAIDs. |
| Regular physiotherapy at the centre* | 4 (21%) | 5 (26%) | 0.719 | |
| Massage or acupuncture | 1 (5%) | 2 (10%) | 0.563 | |
| Number of NSAIDs per week used at follow-up | 2 | 5 | −3 | |
| Total treatment time | 61.00 (7.88) | 60.60 (8.85) | Treatment time is very similar between the two treatment conditions and consistent with the planned treatment duration of treatment. | |
| Satisfaction (scale 0–4) | 3.89 (0.46) | 3.68 (0.75) | 0.21 (−0.20 to 0.62) | Satisfaction of treatment scores were similar between groups with non-significant between group difference. |
| Difficulty (scale 0–5); mean (SD) | 2.26 (0.56) | 2.16 (0.60) | 0.10 (−0.28 to 0.49) | Majority of the participants (75%) reported both treatments as easy. There were no significant between-group difference in difficulty score. |
| Very easy | 0 (0%) | 1 (5%) | ||
| Easy | 15 (75%) | 15 (75%) | ||
| Neither easy nor difficult | 3 (15%) | 2 (10%) | ||
| Difficult | 1 (5%) | 1 (5%) | ||
| Very difficult | 0 (0%) | 0 (0%) |
*Mostly included electrotherapy treatment.
CG, control group; NSAIDS, non-steroidal anti-inflammatory drugs; PEG, pain education group.
Were the feasibility criteria met?
| Criteria | Feasibility criteria met? | Recommendations for full trial |
| Blinding of assessor | Yes | Treatment providers should try to keep the treatment duration close to or equal to 1 hour to avoid any guesses of group allocation between the treatment groups. |
| Recruitment rate | Yes | Incorporating advertisement to recruit the patients was a good idea, which should be considered in the full trial. |
| Attrition rate (in both arms) | Yes | Phone call reminders for the follow-up assessment helped reduce the drop-outs and which should be considered in the future trial. |
| Feasibility of outcome assessment | Yes |
Practice administration of the outcome measures on real patients who are older and have lesser education before the actual recruitment by learning ways to keep patients focused on the questions being asked. Keep the relatives and friends of the patients separate from the participant during screening and assessment. Self-administration of the questionnaires for participants who can read and write could improve the efficiency of completing the screening and data collection forms. Separate the pain-related questionnaires and general questionnaires during administration. |
| Contamination of intervention | Yes | Having an appointment time for follow-up helps avoid contamination. |
| Credibility of treatment | Yes | The credibility scores of the two treatment conditions were within 0.50 SD of each other; therefore, no changes in the treatment conditions are required. |
| Adherence to treatment | Yes | Not many patients read the handbook provided to them. Creating interesting short audios or videos with the key messages may be helpful for improving the adherence to home advice. |
| Difficulty level of the intervention | No | A large proportion of patients reported the interventions to be ‘easy’. The complexity of the pain education content may be increased by providing more complex neurophysiological knowledge to the patients. However, this may demand longer duration of treatment time, and/or compromise the effectiveness of the intervention, and may require pretesting of the changed intervention before using it in the full trial. |
Figure 2Participant flow diagram.
Results of secondary outcome measures: within-group and between-group differences
| Measures | Pain education group | Control group | Between-group difference | |||||
| Baseline Mean (SD) | Follow-up | Change (95% CI) | Baseline mean (SD) | Follow-up | Difference (95% CI) |
| Difference | |
| Pain intensity† | 54.38 (3.48) | 49.14 (3.77) | 5.28*** (2.91 to 7.65) | 52.72 (2.45) | 50.95 (6.54) | 1.72 (−0.82 to 4.26) | 2.16 | 3.56* (0.21 to 6.91) |
| Pain interference† | 62.28 (6.62) | 57.67 (5.80) | 4.47** (1.91 to 7.04) | 58.94 (7.69) | 56.13 (8.24) | 3.03* (0.69 to 5.36) | 0.88 | 1.45 (−1.90 to 4.79) |
| Sleep disturbance† | 51.84 (7.68) | 43.74 (5.31) | 7.62** (3.50 to 11.74) | 45.63 (8.71) | 42.25 (8.41) | 3.49 (−0.12 to 7.10) | 1.58 | 4.13 (−1.16 to 9.42) |
| Depression† | 56.99 (8.08) | 48.25 (8.36) | 8.89*** (5.28 to 12.50) | 53.60 (11.25) | 49.49 (10.29) | 4.61* (0.69 to 8.54) | 1.68 | 4.27 (−0.88 to 9.42) |
| Quality of life | 5.70 (1.22) | 6.42 (0.77) | -0.79* (-1.42 to -0.15) | 6.10 (1.21) | 6.58 (1.22) | -0.47 (−1.04 to 0.09) | −0.78 | −0.32 (−1.13 to 0.50) |
| Pain catastrophising | 22.70 (11.00) | 11.16 (7.59) | 11.63*** (7.19 to 16.07) | 20.50 (12.56) | 16.10 (12.16) | 5.47** (1.79 to 9.16) | 2.24 | 6.16* (0.59 to 11.72) |
| Resilience | 26.95 (9.14) | 28.61 (5.55) | -1.39 (−4.19 to 1.41) | 28.60 (8.08) | 27.00 (8.08) | 1.95 (−2.02 to 5.92) | −1.43 | −3.34 (−8.07 to 1.40) |
| Global rating of change | – | 5.16 (0.69) | – | – | 5.37 (0.64) | – | −0.95 | −0.21 (−0.66 to 0.24) |
*Significant at p<0.05.
**Significant at p<0.01.
***Significant at p<0.001.
†T-scores are reported.